MitoCareX Bio News
2 articlesN2OFF, Inc. Enters Agreement to Acquire MitoCareX Bio Ltd. to Expand Cancer Therapeutics Portfolio
growth-positive
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
SciSparc Ltd, a clinical-stage pharmaceutical company, announced that its joint venture, MitoCareX Bio Ltd, is expanding its research into pancreatic cancer following promising in-vitro results. MitoCareX, which focuses on drug discovery targeting the mitochondrial SLC25 protein family, has achieved positive results using pancreatic cancer cell lines. This expansion marks a significant step in their therapeutic ambitions, adding to their existing focus on non-small cell lung cancer. MitoCareX is also developing a predictive AI model to explore broader chemical spaces for novel anti-cancer treatments. Pancreatic cancer is notably aggressive with a low survival rate, highlighting the importance of this research. SciSparc continues to develop cannabinoid-based pharmaceuticals for various disorders and owns a subsidiary selling hemp seed oil products.
Product StagePartners